MedTrace Logo

Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS

NCT03362294 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-23

No results posted yet for this study

Summary

This is a phase IIa study with GA Depot in subjects with Primary Progressive MS. GA Depot will be administered intramuscularly (IM), once every four weeks for 148 weeks.

The purpose of this study is to assess the safety and efficacy of GA Depot to slow the accumulation of disability progression in subjects with Primary Progressive MS.

Conditions

Interventions

DRUG

GA Depot 40mg once monthly

Once-a-month long-acting intramuscular injection of 40mg Glatiramer Acetate (GA Depot)

DRUG

GA Depot 25mg once monthly

Once-a-month long-acting intramuscular injection of 25mg Glatiramer Acetate (GA Depot)

Sponsors & Collaborators

  • Mapi Pharma Ltd.

    lead INDUSTRY

Principal Investigators

  • Arnon Karni, MD · Coordinating PI

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-11
Primary Completion
2025-06-20
Completion
2025-06-20

Countries

  • Israel
  • Moldova

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03362294 on ClinicalTrials.gov